Prostatype Genomics AB Logo

Prostatype Genomics AB

Provides a genetic test to assess prostate cancer aggressiveness and guide treatment choices.

PROGEN | ST

Overview

Corporate Details

ISIN(s):
SE0022574554 (+2 more)
LEI:
549300JO6MPCGPVHVU91
Country:
Sweden
Address:
Gustav III:s Boulevard 34, 169 73 Solna
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. The test is designed to provide a comprehensive assessment of the aggressiveness of diagnosed prostate cancer, particularly for patients with localized disease. It serves as a decision-making tool for clinicians and patients to help determine appropriate treatment strategies. The Prostatype® system uses existing biopsy tissue to analyze the expression of three key genes. This genetic data is combined with standard clinical parameters (PSA, Gleason Score, Tumor Stage) to calculate a proprietary P-score, which quantifies the risk of cancer mortality. By offering a more precise prognosis, the test aims to minimize both over- and under-treatment, thereby improving patient quality of life and saving healthcare resources.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prostatype Genomics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prostatype Genomics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prostatype Genomics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Rafael Holdings, Inc. Logo
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
Rain Enhancement Technologies Holdco, Inc. Logo
Develops ionization tech to generate rain and mitigate fog for water-scarce regions.
United States of America
RAIN
Rallybio Corp Logo
Develops therapies for severe and rare diseases in hematology and complement dysregulation.
United States of America
RLYB
RaQualia Pharma Inc. Logo
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan
4579
RECURSION PHARMACEUTICALS, INC. Logo
AI-driven biotech accelerating drug discovery for rare diseases and oncology.
United States of America
RXRX
RELMADA THERAPEUTICS, INC. Logo
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
RenovoRx, Inc. Logo
Develops a device platform for delivering targeted therapies directly to solid tumors.
United States of America
RNXT
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan
4978

Talk to a Data Expert

Have a question? We'll get back to you promptly.